QR Code

Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases

Background: Patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations frequently develop brain metastases (BM). While KRAS G12C was once considered an undruggable target, the emergence of selective inhibitors has transformed it into a viable therapeutic option. However, effectiv...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Danming He, Yixiang Zhu, Jia Zhong, Hongqing Cai, Li Yuan, Wei Zhuang, Yan He, Xu Yang, Linjie Fan, Kailun Fei, Boyang Sun, Jie Zhao, Jinghong Xian, Xue Zhang, Zixiao Ma, Zhijie Wang, Jianchun Duan, Weimin Li, Hua Bai, Jie Wang
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2026-06-01
Rangatū:Journal of the National Cancer Center
Ngā marau:
KRAS G12C mutation
NSCLC
Targeted therapy
Brain metastases
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S266700542500122X
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite